Armistice Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $85M | Sell |
676,024
-324,166
| -32% | -$40.7M | 1.47% | 5 |
|
|
2025
Q1 | $111M | Buy |
1,000,190
+108,190
| +12% | +$12M | 1.66% | 4 |
|
|
2024
Q4 | $122M | Buy |
892,000
+710,619
| +392% | +$97M | 1.66% | 5 |
|
|
2024
Q3 | $20.9M | Sell |
181,381
-797,107
| -81% | -$91.8M | 0.33% | 54 |
|
|
2024
Q2 | $135M | Sell |
978,488
-45,251
| -4% | -$6.23M | 1.69% | 3 |
|
|
2024
Q1 | $141M | Sell |
1,023,739
-24,261
| -2% | -$3.35M | 1.87% | 2 |
|
|
2023
Q4 | $138M | Sell |
1,048,000
-168,365
| -14% | -$22.2M | 1.89% | 2 |
|
|
2023
Q3 | $137M | Sell |
1,216,365
-433,635
| -26% | -$48.8M | 2.1% | 3 |
|
|
2023
Q2 | $156M | Buy |
1,650,000
+58,000
| +4% | +$5.47M | 2.25% | 1 |
|
|
2023
Q1 | $161M | Buy |
1,592,000
+692,000
| +77% | +$70M | 2.32% | 1 |
|
|
2022
Q4 | $107M | Sell |
900,000
-424,000
| -32% | -$50.6M | 1.88% | 8 |
|
|
2022
Q3 | $141M | Hold |
1,324,000
| – | – | 2.44% | 5 |
|
|
2022
Q2 | $129K | Buy |
1,324,000
+674,000
| +104% | +$65.7K | 2.25% | 7 |
|
|
2022
Q1 | $60.9M | Buy |
+650,000
| New | +$60.9M | 1.18% | 23 |
|